Prescribing in general practice for people with coronary heart disease; Equity by age, sex, ethnic group and deprivation

Ethnicity and Health

Volumn 16, Issue 2, 2011, Pages 107-123

  Mathur, Rohini ^a   Badrick, Ellena ^a   Boomla, Kambiz ^a   Bremner, Stephen ^a   Hull, Sally ^a   Robson, John ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

coronary heart disease; deprivation; equity; ethnicity; general practice; prescribing

Indexed keywords

AGE STRUCTURE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES; DISEASE PREVALENCE; DRUG PRESCRIBING; ETHNIC GROUP; ETHNICITY; HEALTH SERVICES; LIPID; MORBIDITY; MULTIVARIATE ANALYSIS; SEX DETERMINATION;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ETHNIC GROUP; ETHNOLOGY; FEMALE; GENERAL PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; SEX RATIO; SOCIOECONOMICS; STATISTICS; UNITED KINGDOM;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ETHNIC GROUPS; FAMILY PRACTICE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; LONDON; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS;

EAST LONDON; EASTERN CAPE; SOUTH AFRICA; UNITED KINGDOM;

EID: 79957495361     PISSN: 13557858     EISSN: 14653419     Source Type: Journal    
DOI: 10.1080/13557858.2010.540312     Document Type: Article

References (65)

1. Antman, E.M., et al., 2004. ACC/AHA guidelines for the management of patients with STelevation myocardial infarction: a report of the American College of Cardiology/American
2. Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation, 110, e82-e292.
3. Ashworth, M., et al., 2007. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. Journal of Public Health (Oxf), 29, 40-47.
4. Atri, J., et al., 1996. Fair shares in health care? Ethnic and socioeconomic influences on recording of preventive care in selected inner London general practices. Healthy Eastenders Project. BMJ, 312, 614-617. (Pubitemid 26079600)
5. Balarajan, R., 1995. Ethnicity and variations in the nation's health. Health Trends, 27, 114-119.
6. Barakat, K., et al., 2003. Bangladeshi patients present with non-classic features of acute myocardial infarction and are treated less aggressively in east London, UK. Heart, 89, 276-279. (Pubitemid 36241538)
7. Benner, J.S., et al., 2009. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. American Journal of Health System Pharmacy, 66, 1471-1477.
8. Bhopal, R., et al., 1999. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ, 319, 215-220. (Pubitemid 29338688)
9. Britton, A., et al., 2004. Does access to cardiac investigation and treatment contribute to social and ethnic differences in coronary heart disease? Whitehall II prospective cohort study. BMJ, 329, 318-324.
10. Brookhart, M.A., et al., 2007. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Archives of Internal Medicine, 167, 847-852. (Pubitemid 46658345)
11. Campbell, S.M., et al., 2009. Effects of pay for performance on the quality of primary care in England. New England Journal of Medicine, 361, 368-378.
12. Chapman, R.H., et al., 2008. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging, 25, 885-892.
13. Chisholm, J., 1990. The Read clinical classification. BMJ, 300, 1092. (Pubitemid 20158094)
14. Cooper, A.S., et al., 2007. Clinical guidelines and evidence review for post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners.
15. Crawley, D., et al., 2009. Impact of pay for performance on quality of chronic disease management by social class group in England. Journal of the Royal Society of Medicine, 102, 103-107.
16. Dewilde, S., et al., 2008. Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. Heart, 94, 83-88.
17. Ebrahim, S., et al., 1999. What role for statins? A review and economic model. Health Technology Assessment, 3 (i-iv), 1-91.
18. Enriquez, J.R., et al., 2008.Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gender Medicine, 5, 53-61. (Pubitemid 351506546)
19. Exner, D.V., et al., 2001. Lesser response to angiotensin-converting- enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. The New England Journal of Medicine, 344, 1351-1357. (Pubitemid 32378389)
20. Forouhi, N.G., et al., 2006. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. Diabetologia, 49, 2580-2588.
21. Gemmill, M.C., Thomson, S., and Mossialos, E., 2008. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. International Journal of Equity in Health, 7, 12-34.
22. Gibbs, C.R., Beevers, D.G., and Lip, G.Y., 1999. The management of hypertensive disease in black patients. QJM, 92, 187-192. (Pubitemid 29184881)
23. Gibson, A., et al., 2002. Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. Health Place, 8, 47-60. (Pubitemid 34141680)
24. Gill, P.S., et al., 2004. The use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England. British Journal of General Practice, 54, 442-443. (Pubitemid 38771891)
25. Gnavi, R., et al., 2007. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. European Journal of Public Health, 17, 492-496. (Pubitemid 350033999)
26. Graham, D.J., et al., 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 292, 2585-2590. (Pubitemid 39577514)
27. Greater London Authority (GLA), 2008. 2007 Round demographic projections. London: Greater London Authority Data Management and Analysis Group.
28. Hippisley-Cox, J., et al., 2001. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ, 322, 832-836.
29. Hippisley-Cox, J., et al., 2005. Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. British Journal of General Practice, 55, 369-375. (Pubitemid 40585211)
30. Hippisley-Cox, J., et al., 2008. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ, 336, 1475-1482. (Pubitemid 351977019)
31. Hollenberg, N.K., 2003. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. Current Hypertension Reports, 5, 183-185.
32. Hull, S.A., et al., 2009. Hospital data may be more accurate than census data in estimating the ethnic composition of general practice populations. Informatics in Primary Care, 17, 67-78.
33. Kotseva, K., et al., 2009. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. European Journal of Cardiovascular Prevention & Rehabilitation, 16, 121-137.
34. Lee, H.Y., Cooke, C.E., and Robertson, T.A., 2008. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. Journal of Managed Care Pharmacy, 14, 271-280. (Pubitemid 351711978)
35. Liao, J.K., 2007. Safety and efficacy of statins in Asians. American Journal of Cardiology, 99, 410-414. (Pubitemid 46149563)
36. Liao, Y., et al., 2010. Decreasing disparity in cholesterol screening in minority communities* findings from the Racial and Ethnic Approaches to Community Health 2010. Journal of Epidemiology and Community Health, 64, 292-299.
37. Maroo, B.P., Lavie, C.J., and Milani, R.V., 2008. Efficacy and safety of intensive statin therapy in the elderly. The American Journal of Geriatric Cardiology, 17, 92-100.
38. Mcdowell, S.E., Coleman, J.J., and Ferner, R.E., 2006. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ, 332, 1177-1181.
39. Millett, C., et al., 2009a. Pay for perfomance and the quality of diabetes management in individuals with and without co-morbid medical conditions. Journal of the Royal Society of Medicine, 102, 369-377.
40. Millett, C., et al., 2009b. Ethnic disparities in coronary heart disease management and pay for performance in the UK. Journal of General Internal Medicine, 24, 8-13.
41. Naqvi, H., et al., 2004. Registering ischaemic heart disease: are we meeting the targets for South Asians? Journal of Public Health (Oxf), 26, 365-368. (Pubitemid 40070454)
42. Nazroo, J., et al., 2009. Ethnic inequalities in access to and outcomes of healthcare: analysis of the Health Survey for England. Journal of Epidemiology and Community Health, 63, 1022-1027.
43. NHS Business Services Authority, 2010. Variation between southern primary care trusts in prescribing of Pravastatin/Simvastatin as a % of all Statins (Quarter to September 2009). London: NHSBA.
44. Office for National Statistics (ONS), 2003. Ethnic group statistics: a guide for the collection and classification of ethnicity data. Newport: Office for National Statistics.
45. Office for National Statistics, 2009. Numbers of deaths and age-standardised death rates from CHD for men and women under 75 by local authority, 2005/2007, United Kingdom. Newport: Office for National Statistics.
46. Office of the Deputy Prime Minister, 2004. The English indices of deprivation. London: Office of the Deputy Prime Minister.
47. Patel, M.G., et al., 2002. Prescribing of lipid lowering drugs to South Asian patients: ecological study. BMJ, 325, 25-26. (Pubitemid 34747938)
48. Qato, D.M., et al., 2010. Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiology and Drug Safety, 19, 834-842. doi: 10.1002/pds.1974
49. Ramsay, S.E., et al., 2005. Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. Journal of Public Health (Oxf), 27, 338-343. (Pubitemid 41752466)
50. Reid, F.D., Cook, D.G., and Whincup, P.H., 2002. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart, 88, 15-19. (Pubitemid 34664992)
51. Robson, J., 2008. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Heart, 94, 1331-1332.
52. Ryan, R.M., A., 2001. Prevalence of ischaemic heart disease and its management with statins and aspirin in general practice in England and Wales, 1994 and 1998. Health Statistics Quarterly, 12, 34-39.
53. Scandinavian Simvastatin Survival Study Group, 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
54. Schedlbauer, A., Davies, P., and Fahey, T., 2010. Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews, 3, CD004371.
55. Shah, N.D., et al., 2009. Long-term medication adherence after myocardial infarction: experience of a community. American Journal of the Medicine, 122, 961.e7-961.e13.
56. Simpson, C.R., Hannaford, P.C., and Williams, D., 2005. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart, 91, 630-634. (Pubitemid 40559355)
57. The Marmot Review, 2010. Fair society, healthy lives; strategic review of health inequalities post-2010: T.M. Review. London: The Marmot Review.
58. Townsend, P., 1991. Deprivation and ill health. Nursing (Lond), 4, 11-15.
59. Verma, A., et al., 2010. Ethnic disparities in diabetes management: a 10-year population-based repeated cross-sectional study in UK primary care. Journal of Public Health (Oxf), 32 (2), 250-258.
60. Ward, P.R., Noyce, P.R., and St Leger, A.S., 2004. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. Journal of Epidemiology and Community Health, 58, 89-96. (Pubitemid 38130474)
61. Ward, P.R., Noyce, P.R., and St Leger, A.S., 2005. Multivariate regression analysis of associations between general practitioner prescribing rates for coronary heart disease drugs and healthcare needs indicators. Journal of Epidemiology and Community Health, 59, 86-87.
62. Whincup, P.H., et al., 2002. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart, 88, 25-29. (Pubitemid 34664994)
63. Wood, D., et al., 1998. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis, 140, 199-270. (Pubitemid 28535317)
64. Yang, Y., et al., 2009. Predictors of medication nonadherence among patients with diabetes in Medicare Part D Programs: a retrospective cohort study. Clinical Therapeutics, 31, 2178-2188.
65. Yusuf, S., et al., 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364, 937-952.